137 related articles for article (PubMed ID: 35150749)
1. Optimizing screening with faecal immunochemical test for both sexes - Cost-effectiveness analysis from Finland.
Heinävaara S; Gini A; Sarkeala T; Anttila A; de Koning H; Lansdorp-Vogelaar I
Prev Med; 2022 Apr; 157():106990. PubMed ID: 35150749
[TBL] [Abstract][Full Text] [Related]
2. Population-based colorectal cancer screening programmes using a faecal immunochemical test: should faecal haemoglobin cut-offs differ by age and sex?
Arana-Arri E; Idigoras I; Uranga B; Pérez R; Irurzun A; Gutiérrez-Ibarluzea I; Fraser CG; Portillo I;
BMC Cancer; 2017 Aug; 17(1):577. PubMed ID: 28851318
[TBL] [Abstract][Full Text] [Related]
3. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer.
Dinh T; Ladabaum U; Alperin P; Caldwell C; Smith R; Levin TR
Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1158-66. PubMed ID: 23542330
[TBL] [Abstract][Full Text] [Related]
4. Optimising colorectal cancer screening in Shanghai, China: a modelling study.
Cenin D; Li P; Wang J; de Jonge L; Yan B; Tao S; Lansdorp-Vogelaar I
BMJ Open; 2022 May; 12(5):e048156. PubMed ID: 35577474
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of the faecal immunochemical test at a range of positivity thresholds compared with the guaiac faecal occult blood test in the NHS Bowel Cancer Screening Programme in England.
Murphy J; Halloran S; Gray A
BMJ Open; 2017 Oct; 7(10):e017186. PubMed ID: 29079605
[TBL] [Abstract][Full Text] [Related]
6. Screening for Colorectal Cancer With Fecal Immunochemical Testing With and Without Postpolypectomy Surveillance Colonoscopy: A Cost-Effectiveness Analysis.
Greuter MJE; de Klerk CM; Meijer GA; Dekker E; Coupé VMH
Ann Intern Med; 2017 Oct; 167(8):544-554. PubMed ID: 28973514
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness and budget impact analyses of colorectal cancer screenings in a low- and middle-income country: example from Thailand.
Phisalprapa P; Supakankunti S; Chaiyakunapruk N
J Med Econ; 2019 Dec; 22(12):1351-1361. PubMed ID: 31560247
[No Abstract] [Full Text] [Related]
8. Cost-effectiveness analysis of colorectal cancer screening in a low incidence country: The case of Saudi Arabia.
Naber SK; Almadi MA; Guyatt G; Xie F; Lansdorp-Vogelaar I
Saudi J Gastroenterol; 2021; 27(4):208-216. PubMed ID: 33835054
[TBL] [Abstract][Full Text] [Related]
9. Optimal use of colonoscopy and fecal immunochemical test for population-based colorectal cancer screening: a cost-effectiveness analysis using Japanese data.
Sekiguchi M; Igarashi A; Matsuda T; Matsumoto M; Sakamoto T; Nakajima T; Kakugawa Y; Yamamoto S; Saito H; Saito Y
Jpn J Clin Oncol; 2016 Feb; 46(2):116-25. PubMed ID: 26685321
[TBL] [Abstract][Full Text] [Related]
10. Gender-specific cut-off levels in colorectal cancer screening with fecal immunochemical test: A population-based study of colonoscopy findings and costs.
Ribbing Wilén H; Saraste D; Blom J
J Med Screen; 2021 Dec; 28(4):439-447. PubMed ID: 34106777
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of Colonoscopy-Based Colorectal Cancer Screening in Childhood Cancer Survivors.
Gini A; Meester RGS; Keshavarz H; Oeffinger KC; Ahmed S; Hodgson DC; Lansdorp-Vogelaar I
J Natl Cancer Inst; 2019 Nov; 111(11):1161-1169. PubMed ID: 30980665
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of colorectal cancer screening using colonoscopy, fecal immunochemical test, and risk score.
Sekiguchi M; Igarashi A; Sakamoto T; Saito Y; Esaki M; Matsuda T
J Gastroenterol Hepatol; 2020 Sep; 35(9):1555-1561. PubMed ID: 32167186
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness and projected national impact of colorectal cancer screening in France.
Hassan C; Benamouzig R; Spada C; Ponchon T; Zullo A; Saurin JC; Costamagna G
Endoscopy; 2011 Sep; 43(9):780-93. PubMed ID: 21623557
[TBL] [Abstract][Full Text] [Related]
14. Efficient organized colorectal cancer screening in Shenzhen: a microsimulation modelling study.
Zhu M; Zhong X; Liao T; Peng X; Lei L; Peng J; Cao Y
BMC Public Health; 2024 Mar; 24(1):655. PubMed ID: 38429684
[TBL] [Abstract][Full Text] [Related]
15. Interval cancers in a population-based screening program for colorectal cancer with gender-specific cut-off levels for fecal immunochemical test.
Ribbing Wilén H; Saraste D; Blom J
J Med Screen; 2022 Sep; 29(3):156-165. PubMed ID: 35257615
[TBL] [Abstract][Full Text] [Related]
16. Fecal occult blood testing when colonoscopy capacity is limited.
Wilschut JA; Habbema JD; van Leerdam ME; Hol L; Lansdorp-Vogelaar I; Kuipers EJ; van Ballegooijen M
J Natl Cancer Inst; 2011 Dec; 103(23):1741-51. PubMed ID: 22076285
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of one versus two sample faecal immunochemical testing for colorectal cancer screening.
Goede SL; van Roon AH; Reijerink JC; van Vuuren AJ; Lansdorp-Vogelaar I; Habbema JD; Kuipers EJ; van Leerdam ME; van Ballegooijen M
Gut; 2013 May; 62(5):727-34. PubMed ID: 22490518
[TBL] [Abstract][Full Text] [Related]
18. Should colorectal cancer screening start at different ages for men and women? Cost-effectiveness analysis for a resource-constrained service.
Thomas C; Mandrik O; Whyte S; Saunders CL; Griffin SJ; Usher-Smith JA
Cancer Rep (Hoboken); 2021 Aug; 4(4):e1344. PubMed ID: 33533190
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness of Personalized Screening for Colorectal Cancer Based on Polygenic Risk and Family History.
Cenin DR; Naber SK; de Weerdt AC; Jenkins MA; Preen DB; Ee HC; O'Leary PC; Lansdorp-Vogelaar I
Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):10-21. PubMed ID: 31748260
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of colorectal cancer screening programmes using sigmoidoscopy and immunochemical faecal occult blood test.
Senore C; Hassan C; Regge D; Pagano E; Iussich G; Correale L; Segnan N
J Med Screen; 2019 Jun; 26(2):76-83. PubMed ID: 30180780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
